Market Overview

US Stock Futures Flat Ahead Of Economic Data

Related TEVA
Teva Settles Patent Litigation with Pfizer on Celebrex; Has Received Tenative FDA Approval for All Strengths; May Start Generic Versions in December
Market Wrap For April 16: Markets Hold On To Gains On Positive Yellen Comments And Economic Data
Pfizer Loses Bid to Hold Celebrex Exclusivity to '15 (Fox Business)
Related CHFC
Wintrust Beats on Q1 Earnings, Lags Revs - Analyst Blog
Wintrust to Acquire Branch of THE National Bank - Analyst Blog

Pre-open movers

US stock futures were mostly flat in early pre-market trade, ahead of consumer sentiment and retail sales data. The producer price index for August and retail sales data for August will be released at 8:30 a.m. ET. The Reuters/University of Michigan's consumer sentiment index for September will be released at 9:55 a.m. ET, while business inventories data for July will be released at 10:00 a.m. ET. Futures for the Dow Jones Industrial Average gained 3 points to 15,249.00, while the Standard & Poor's 500 index futures fell 1.30 points to 1,677.00. Futures for the Nasdaq 100 index declined 2.50 points to 3,176.00.

A Peek Into Global Markets

European markets were lower today, with the Spanish Ibex Index falling 0.17%, London's FTSE 100 index dropping 0.28% and STOXX Europe 600 Index declining 0.15%. German DAX 30 index fell 0.11% and French CAC 40 Index declined 0.18%.

Asian markets ended mostly lower today. China's Shanghai Composite fell 0.86%, while Japan's Nikkei Stock Average rose 0.12%. Australia's ASX/S&P500 dropped 0.45% and Hong Kong's Hang Seng Index declined 0.17% and India's Sensex dropped 0.25%.

Broker Recommendation

Analysts at JP Morgan downgraded Teva Pharmaceutical Industries (NYSE: TEVA) from “overweight” to “neutral.” The target price for Teva has been lowered from $45 to $43.

Teva's shares closed at $38.88 yesterday.

Breaking news

  • Chemical Financial (NASDAQ: CHFC) announced today the pricing of an underwritten public offering of 1,925,000 shares of its common stock at a price of $26.00 per share to the public.To read the full news, click here.
  • LDK Solar Co (NYSE: LDK) announced its engagement of Jefferies LLC as financial advisor for strategic advice in connection with LDK Solar's offshore debt obligations, including the US$-Settled 10% Senior Notes due 2014. To read the full news, click here.
  • OCI Resources LP (NYSE: OCIR) announced today the pricing of its initial public offering of 5,000,000 common units representing limited partner interests in the Partnership at a public offering price of $19.00 per common unit. To read the full news, click here.
  • Alexion Pharmaceuticals (NASDAQ: ALXN), today announced that the Ministry of Health, Labour and Welfare (MHLW) in Japan has approved the use of Soliris® (eculizumab) for the treatment of pediatric and adult patients with atypical hemolytic uremic syndrome (aHUS), a life-threatening ultra-rare disorder. To read the full news, click here.

Posted-In: JP Morgan US Stock FuturesNews Eurozone Futures Global Pre-Market Outlook Markets

 

Most Popular

Related Articles (ALXN + CHFC)

Around the Web, We're Loving...

Partner Network

Get Benzinga's News Delivered Free